Last reviewed · How we verify
Gasmotin — Competitive Intelligence Brief
phase 3
Cytochrome P450 1A2, Cytochrome P450 2C19, Cytochrome P450 2C9
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Gasmotin (Gasmotin) — Daewoong Pharmaceutical Co. LTD..
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Gasmotin TARGET | Gasmotin | Daewoong Pharmaceutical Co. LTD. | phase 3 | Cytochrome P450 1A2, Cytochrome P450 2C19, Cytochrome P450 2C9 | ||
| Gasmotin | MOSAPRIDE | marketed | mosapride | Cytochrome P450 1A2, Cytochrome P450 2C19, Cytochrome P450 2C9 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Gasmotin — Competitive Intelligence Brief. https://druglandscape.com/ci/gasmotin. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing